Dengvaxia Is Sighted To Be The First Accredited Vaccine Against Dengue in the European Union
The European Union recently authorized the Dengvaxia vaccine in the market and it’s sighted to be the first accredited vaccine against dengue.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is an organization responsible for elaborating the information regarding the medicinal products for human use.
Based on the report from Philstar, the CHMP recently recommended and authorized the Dengvaxia vaccine to the market. The vaccine is manufactured by French pharmaceutical Sanofi-Pasteur.
During the administration of Benigno Aquino III, the Dengvaxia vaccine program was launched with at least 800,000 Filipino children administered.
The program was suspended last year after Sanofi Pasteur advised that the vaccine might cause severe dengue symptoms if it is given to individuals who have never experienced dengue.
Despite the controversy, the CHMP expressed that the dengue vaccine has been proven to be effective for the young and old people with virus serotypes 1, 2, 3, and 4.
According to the report, CHMP declared that the safety and benefits of the Dengvaxia was evaluated into 31 clinical studies and was conducted mostly in dengue-endemic areas like Latin America and the Asia Pacific.
41,000 with ages ranging from 9 months to 60 years old participated in the study.
However, the CHMP recommended limiting the use of the Dengvaxia vaccine to individuals with previous virus infection.
The European Medicines Agency stated that the opinion made by the CHMP regarding the vaccine is still on the process.
Based on the report, the opinion should be sent to the European Commision for the acceptance of the decision on to European Union marketing authorization.
“Once a marketing authorization has been granted, decisions about price and reimbursement will take place at the level of each member state,” the European Medicines Agency said.
What can you say about this article? Leave your comments and reactions below.
